Kingfa Science & Technology (India) Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 5, 2025, 4:08 pm

Quick Insight

Kingfa Science & Technology (India) Ltd, operating in the plastics sector, presents a compelling investment profile with a current share price of ₹3,612 and a market capitalization of ₹4,375 crore. The company boasts a robust P/E ratio of 28.6, indicating strong growth expectations, while its impressive return on equity (ROE) of 23.2% and return on capital employed (ROCE) of 30.6% reflect efficient management of resources. With a net profit of ₹153 crore and a comfortable interest coverage ratio (ICR) of 33.55x, Kingfa demonstrates financial stability. However, a P/BV of 4.03x suggests it may be overvalued relative to its book value. Given the high promoter holding of 74.99%, investor confidence remains strong, yet potential investors should weigh the elevated valuation against the company’s solid fundamentals before making decisions.

Competitors of Kingfa Science & Technology (India) Ltd

All Competitor Stocks of Kingfa Science & Technology (India) Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:20 pm

Below is a detailed analysis of the quarterly data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 462.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 462.00 Cr., marking a decrease of 8.00 Cr..
• For Expenses, as of Jun 2025, the value is 404.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 409.00 Cr. (Mar 2025) to 404.00 Cr., marking a decrease of 5.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 2.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 54.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 54.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 2.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 32.86. The value appears to be declining and may need further review. It has decreased from 34.60 (Mar 2025) to 32.86, marking a decrease of 1.74.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 5:00 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:50 am

Below is a detailed analysis of the balance sheet data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 12.00 Cr..
• For Reserves, as of Mar 2025, the value is 716.00 Cr.. The value appears strong and on an upward trend. It has increased from 576.00 Cr. (Mar 2024) to 716.00 Cr., marking an increase of 140.00 Cr..
• For Borrowings, as of Mar 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 33.00 Cr. (Mar 2024) to 43.00 Cr., marking an increase of 10.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 384.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 373.00 Cr. (Mar 2024) to 384.00 Cr., marking an increase of 11.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,156.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 994.00 Cr. (Mar 2024) to 1,156.00 Cr., marking an increase of 162.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 244.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2024) to 244.00 Cr., marking a decrease of 8.00 Cr..
• For CWIP, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 39.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 871.00 Cr.. The value appears strong and on an upward trend. It has increased from 740.00 Cr. (Mar 2024) to 871.00 Cr., marking an increase of 131.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,156.00 Cr.. The value appears strong and on an upward trend. It has increased from 994.00 Cr. (Mar 2024) to 1,156.00 Cr., marking an increase of 162.00 Cr..

Notably, the Reserves (716.00 Cr.) exceed the Borrowings (43.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Kingfa Science & Technology (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 101.17. This value is within the healthy range. It has increased from 67.22 (Mar 23) to 101.17, marking an increase of 33.95.
• For Diluted EPS (Rs.), as of Mar 24, the value is 101.17. This value is within the healthy range. It has increased from 67.22 (Mar 23) to 101.17, marking an increase of 33.95.
• For Cash EPS (Rs.), as of Mar 24, the value is 116.35. This value is within the healthy range. It has increased from 78.90 (Mar 23) to 116.35, marking an increase of 37.45.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 486.00. It has increased from 384.78 (Mar 23) to 486.00, marking an increase of 101.22.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 486.00. It has increased from 384.78 (Mar 23) to 486.00, marking an increase of 101.22.
• For Dividend / Share (Rs.), as of Mar 24, the value is 10.00. This value exceeds the healthy maximum of 3. It has increased from 0.00 (Mar 23) to 10.00, marking an increase of 10.00.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 1,228.45. It has increased from 1,159.08 (Mar 23) to 1,228.45, marking an increase of 69.37.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 155.39. This value is within the healthy range. It has increased from 107.56 (Mar 23) to 155.39, marking an increase of 47.83.
• For PBIT / Share (Rs.), as of Mar 24, the value is 140.21. This value is within the healthy range. It has increased from 95.89 (Mar 23) to 140.21, marking an increase of 44.32.
• For PBT / Share (Rs.), as of Mar 24, the value is 135.58. This value is within the healthy range. It has increased from 90.49 (Mar 23) to 135.58, marking an increase of 45.09.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 101.17. This value is within the healthy range. It has increased from 67.22 (Mar 23) to 101.17, marking an increase of 33.95.
• For PBDIT Margin (%), as of Mar 24, the value is 12.64. This value is within the healthy range. It has increased from 9.27 (Mar 23) to 12.64, marking an increase of 3.37.
• For PBIT Margin (%), as of Mar 24, the value is 11.41. This value is within the healthy range. It has increased from 8.27 (Mar 23) to 11.41, marking an increase of 3.14.
• For PBT Margin (%), as of Mar 24, the value is 11.03. This value is within the healthy range. It has increased from 7.80 (Mar 23) to 11.03, marking an increase of 3.23.
• For Net Profit Margin (%), as of Mar 24, the value is 8.23. This value is within the healthy range. It has increased from 5.79 (Mar 23) to 8.23, marking an increase of 2.44.
• For Return on Networth / Equity (%), as of Mar 24, the value is 20.81. This value is within the healthy range. It has increased from 17.47 (Mar 23) to 20.81, marking an increase of 3.34.
• For Return on Capital Employeed (%), as of Mar 24, the value is 28.66. This value is within the healthy range. It has increased from 24.65 (Mar 23) to 28.66, marking an increase of 4.01.
• For Return On Assets (%), as of Mar 24, the value is 12.32. This value is within the healthy range. It has increased from 8.05 (Mar 23) to 12.32, marking an increase of 4.27.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.05. This value is within the healthy range. It has decreased from 0.08 (Mar 23) to 0.05, marking a decrease of 0.03.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 1.48. It has decreased from 1.49 (Mar 23) to 1.48, marking a decrease of 0.01.
• For Current Ratio (X), as of Mar 24, the value is 1.80. This value is within the healthy range. It has increased from 1.37 (Mar 23) to 1.80, marking an increase of 0.43.
• For Quick Ratio (X), as of Mar 24, the value is 1.20. This value is within the healthy range. It has increased from 0.83 (Mar 23) to 1.20, marking an increase of 0.37.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.11. This value is within the healthy range. It has increased from 3.84 (Mar 23) to 4.11, marking an increase of 0.27.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 33.55. This value is within the healthy range. It has increased from 19.95 (Mar 23) to 33.55, marking an increase of 13.60.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 22.84. This value is within the healthy range. It has increased from 13.47 (Mar 23) to 22.84, marking an increase of 9.37.
• For Enterprise Value (Cr.), as of Mar 24, the value is 2,398.91. It has increased from 1,621.01 (Mar 23) to 2,398.91, marking an increase of 777.90.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.61. This value is within the healthy range. It has increased from 1.15 (Mar 23) to 1.61, marking an increase of 0.46.
• For EV / EBITDA (X), as of Mar 24, the value is 12.75. This value is within the healthy range. It has increased from 12.44 (Mar 23) to 12.75, marking an increase of 0.31.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.60. This value is within the healthy range. It has increased from 1.14 (Mar 23) to 1.60, marking an increase of 0.46.
• For Price / BV (X), as of Mar 24, the value is 4.03. This value exceeds the healthy maximum of 3. It has increased from 3.45 (Mar 23) to 4.03, marking an increase of 0.58.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.60. This value is within the healthy range. It has increased from 1.14 (Mar 23) to 1.60, marking an increase of 0.46.
• For EarningsYield, as of Mar 24, the value is 0.05. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness